# Driving smarter investment in women’s health

- Link: https://www.directorstalkinterviews.com/driving-smarter-investment-in-women-s-health/4121194460
- Published: 2025-04-29T14:58:00+01:00
- Author: Amilia Stone

The FemHealth Integrates Conference in Manchester created a dynamic space where 
innovation met necessity, shining a light on the systemic barriers that continue
to impact women’s health outcomes. Voices from across healthcare, investment, research
and technology came together to map the future of women’s health, highlighting the
urgency for smarter strategies, deeper representation and unified thinking. It became
clear that the next frontier in women’s health will be defined by the intelligent
application of data, greater inclusivity and targeted investment.

One of the most pressing issues discussed was the stark regional divide in healthcare
outcomes across England. Women living in the North continue to face poorer health
compared to those in the South, a disparity driven by longstanding inequalities 
in resources, access and support. The conference highlighted the vital role of innovation
hubs like Bruntwood SciTech in addressing these gaps and the importance of regional
collaboration to even out healthcare delivery across the country.

The conversation around clinical trials revealed the progress made but also exposed
how far there is still to go. Although policies have shifted to include women in
research since the late 20th century, trial demographics remain heavily skewed towards
men. Some studies still feature a staggering imbalance of one woman to fifty men.
Smarter, more inclusive trial designs and outreach strategies are critical, as is
the application of advanced data science to ensure outcomes truly reflect the diverse
real-world population. The opportunities for transformation here are both vast and
necessary.

The issue of investment inequality was equally stark. With only 15% of angel investors
being women and the majority based in London, innovation outside the capital struggles
to attract the funding it needs. This imbalance continues to limit the growth of
women-led and female-focused health innovations, particularly within FemTech. However,
shifting political landscapes, especially in the US, suggest new windows are opening
for international investors ready to recognise the value in backing female founders.
For investors, the message is clear—funding women’s health is not only an ethical
choice but a strategic advantage.

The limitations caused by siloed health data were also sharply in focus. Women’s
health information is often compartmentalised by life stage, failing to capture 
the continuous and connected nature of the female health journey. There is a massive
opportunity for Healthcare Marketers and strategists to utilise AI and unified data
systems to map the full patient experience, leading to more nuanced and personalised
solutions. Investment in integrated approaches, as supported by findings from The
Lancet Commission, promises profound impacts on morbidity, mortality and economic
growth.

Cultural transformation was another standout theme. Organisations across the healthcare
sector are redefining internal cultures through commitments to equal parental leave,
transparent pay structures and stronger workplace equity. These changes are not 
mere corporate niceties; they reflect a deeper brand authenticity that resonates
with patients and consumers alike. In a healthcare environment increasingly driven
by trust and personal values, how a company operates internally is becoming just
as important as the solutions it provides externally.

For those working in Healthcare Marketing and investment, the signals are loud and
clear. The future of women’s health demands strategies informed by life journeys
rather than symptoms, shaped by real-world data rather than assumptions, and delivered
by organisations that reflect the diversity they aim to serve. The foundations have
been laid, and the insights from FemHealth Integrates confirm that the path forward
is rich with opportunity for those bold enough to build it.

Talking Medicines is a leading innovator in patient-centric data science, dedicated
to transforming pharmaceutical marketing through real-world patient insights powered
by AI. Their solutions empower companies to better understand patient journeys and
create truly effective healthcare communications.

_**[Tern plc](https://www.directorstalkinterviews.com/company/tern-plc/tern.l) **(
[LON:TERN](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)) backs
exciting, high growth IoT innovators in Europe. They provide support and create 
a genuinely collaborative environment for talented, well-motivated teams. _

Share on:
